Senate's Medical Innovation Bill Takes Cures' Shape
This article was originally published in The Pink Sheet Daily
HELP Committee chairman finally calls his package a companion to 21st Century Cures bill, but more work is necessary to bring it in line with the House legislation.
You may also be interested in...
White House says all guidances, as well as proposed rules, must be submitted to OMB for a determination whether they are major or minor.
Public scrutiny has made 483 results much more impactful than intended, says Howard Sklamberg, former FDA deputy commissioner for global regulatory operations and policy. He reminds stakeholders that information in them is preliminary.
OPEN ACT would provide additional six months of exclusivity when existing drugs are approved for rare diseases; congressional debate over the measure could get bogged down in drug pricing issues.